Document is current
Any future updates will be listed below
-
Authors
Swan, Joshua T.
Rizk, Elsie
Duong, Phuong Y
Alghamdi, Bader M.
Kaur, Navjot
Nagaraj, Sudha
Brown, Anthony E.
Flores, Eleazar
Spence, Nathan
Tajchman, Sharla
-
Funding
Funding for this research was provided by:
Pfizer
Eli Lilly
- License Information
-
More Information
Article History
Received: 16 March 2023
Accepted: 21 September 2023
First Online: 27 September 2023
Declarations
:
: The Houston Methodist Research Institute’s Institutional Review Board approved this study with a waiver of informed consent (approval number PRO00024493). All study methods were carried out in accordance with the relevant guidelines and regulations including the Declaration of Helsinki.
: Not applicable.
: Co-authors Sharla Tajchman and Nathan Spence, who are employees at Pfizer with stock and/or stock options, participated in study design, interpretation of study data, and writing of the manuscript. All remaining authors declare no conflict of interest.
: This work was not previously presented before submission to the journal.
